PREVALENCE OF POTENTIAL DRUG-DRUG INTERACTIONS WITH RITONAVIR-CONTAINING COVID-19 MEDICATIONS AMONG THE ADULT PATIENT POPULATION IN AUSTRALIA: ANALYSIS OF PHARMACEUTICAL BENEFITS SCHEME 10% SAMPLE (PBS10) CLAIMS

PREVALENCE OF POTENTIAL DRUG-DRUG INTERACTIONS WITH RITONAVIR-CONTAINING COVID-19 MEDICATIONS AMONG THE ADULT PATIENT POPULATION IN AUSTRALIA: ANALYSIS OF PHARMACEUTICAL BENEFITS SCHEME 10% SAMPLE (PBS10) CLAIMS

Intro: Oral antiviral agents with differing modes of action are now available for the treatment of COVID-19. However, potentially life-threatening drug-drug interactions (DDIs) may occur if patients’ underlying co-morbidities are treated with medications that are contraindicated with ritonavir-conta...

Full description

Bibliographic Details
Main Authors:	C. Cameron, W.-T. Chen, W.-H. Tan, Y. Chen, C. Lam, E. Igho-Osagie
Format:	Article
Language:	English
Published:	Elsevier 2023-05-01
Series:	International Journal of Infectious Diseases
Online Access:	http://www.sciencedirect.com/science/article/pii/S1201971223003508

Similar Items

Levodopa use in Australia: an analysis of Pharmaceutical Benefits Scheme 10% data
by: Andrew Evans, et al.
Published: (2024-01-01)

Identifying Incident Cancer Cases in Medicine Dispensing Claims: A Validation Study Using Australia’s Pharmaceutical Scheme (PBS) Data
by: Benjamin Daniels, et al.
Published: (2020-12-01)

Number of drugs provided by the Pharmaceutical Benefits Scheme and mortality and hospital utilization in Australia, 2002–2019
by: Frank R. Lichtenberg
Published: (2023-12-01)

Capture of systemic anticancer medicines in Pharmaceutical Benefits Scheme (PBS) data likely higher than previously reported – Authors’ reply
by: Nicola Creighton, et al.
Published: (2020-06-01)

Capture of systemic anticancer medicines in Pharmaceutical Benefits Scheme (PBS) data likely higher than previously reported
by: Dominique L Favell, et al.
Published: (2020-06-01)

Retrospective comparison of Australia’s Pharmaceutical Benefits Scheme claims data with prescription data in HER2-positive early breast cancer patients, 2008–2012
by: Carole Harris, et al.
Published: (2017-12-01)

Operationalization and validation of a novel method to calculate adherence to polypharmacy with refill data from the Australian pharmaceutical benefits scheme (PBS) database
by: Arnet I, et al.
Published: (2018-09-01)

A novel validated UPLC method for quantitation of lopinavir and ritonavir in bulk drug and pharmaceutical formulation with its impurities
by: Gnana Deepika Killi, et al.
Published: (2014-04-01)

High drug loading solid lipid nanoparticles, nanostructured lipid carriers and nanoemulsions for the dual drug delivery of the HIV drugs darunavir and ritonavir
by: Heba Elkateb, et al.
Published: (2023-10-01)

Variations in utilisation of colorectal cancer services in South Australia indicated by MBS/PBS benefits: a benefit incidence analysis
by: Anita Lal, et al.
Published: (2022-04-01)

P661: POPULATION-WIDE PATTERNS OF CARE IN CHRONIC LYMPHOCYTIC LEUKEMIA IN AUSTRALIA: AN ANALYSIS OF THE PHARMACEUTICAL BENEFITS SCHEME DATASET
by: C. Tam, et al.
Published: (2022-06-01)

PB2082: POPULATION-WIDE PATTERNS OF CARE IN MANTLE CELL LYMPHOMA IN AUSTRALIA: AN ANALYSIS OF THE PHARMACEUTICAL BENEFITS SCHEME DATASET
by: C. Tam, et al.
Published: (2022-06-01)

Ins and outs of the pharmaceutical benefits scheme
by: Bennett, J, et al.
Published: (2003)

DRUG-DRUG INTERACTIONS BETWEEN ARTEMETHER/LUMEFANTRINE AND LOPINAVIR/RITONAVIR IN HIV NEGATIVE HEALTHY VOLUNTEERS
by: German, P, et al.
Published: (2008)

Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment
by: Paola Magro, et al.
Published: (2021-03-01)

HIV treatment regimens and adherence to national guidelines in Australia: an analysis of dispensing data from the Australian pharmaceutical benefits scheme
by: Nila J. Dharan, et al.
Published: (2019-01-01)

Potential clinically significant life-threatening drug–drug interactions of lopinavir and ritonavir used in the treatment of COVID-19
by: Mohitosh Biswas, et al.
Published: (2020-01-01)

Liquisolid pellets: A pharmaceutical technology strategy to improve the dissolution rate of ritonavir
by: Brenda De Espíndola, et al.
Published: (2019-07-01)

Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer
by: Kaleem Anwar, PharmD, et al.
Published: (2023-02-01)

Drug-drug interactions in pharmaceutical development /
by: Li, A. P.
Published: (2008)

The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins
by: Nancy H.C. Loos, et al.
Published: (2023-06-01)

Influence of Carrier (Polymer) Type and Drug-Carrier Ratio in the Development of Amorphous Dispersions for Solubility and Permeability Enhancement of Ritonavir
by: Vivek S. Dave, et al.
Published: (2017-09-01)

Influence of Carrier (Polymer) Type and Drug-Carrier Ratio in the Development of Amorphous Dispersions for Solubility and Permeability Enhancement of Ritonavir
by: Vivek S. Dave, et al.
Published: (2017-09-01)

Interactions that matter: 10 Antiarrhythmic drugs
by: Aronson, J
Published: (1987)

A 10-Year Histopathologic Audit of Uterine Cervical Biopsies in Warri, Nigeria
by: Emmanuel Igho Odokuma
Published: (2019-03-01)

Depolymerization of P4HB and PBS Waste and Synthesis of the Anticancer Drug Busulfan from Plastic Waste
by: Daniel L. Lourenço, et al.
Published: (2022-03-01)

Patients' claims regarding drug allergies
by: Dmitrović Radmila R., et al.
Published: (2020-01-01)

Malpractice Claims in Ophthalmology: A 10-Year Review
by: Mehmet Hakan Özdemir, et al.
Published: (2014-01-01)

he impact of drug-loading factors on the solid-state form of ritonavir-mesoporous silica systems
by: Tanweer Al-Dagamin, et al.
Published: (2022-11-01)

Drug delivery and targeting : for pharmacists and pharmaceutical scientists /
by: Hillery, Anya M., et al.
Published: (2001)

Simultaneous green TLC determination of nirmatrelvir and ritonavir in the pharmaceutical dosage form and spiked human plasma
by: Mohamed S. Imam, et al.
Published: (2023-04-01)

Effect of nanoencapsulation on the phenomenon of drug interaction between anti-<it>M.avium</it> drug, rifabutin and anti-HIV drug, ritonavir by employing poly (lactide-co-glycolide) nanoparticles
by: Grewal Tapinder, et al.
Published: (2012-05-01)

Rational Use of Drugs: Pharmaceutical Aspects of the Drug Selection
by: Natalya B. Rostova, PhD, ScD, et al.
Published: (2012-09-01)

Advances in Antitumor Nano-Drug Delivery Systems of 10-Hydroxycamptothecin
by: Chen Y, et al.
Published: (2022-09-01)

Retinal toxicity with Ritonavir
by: Yufei Tu, et al.
Published: (2016-04-01)

Case report: Paralytic ileus resulted from nirmatrelvir/ritonavir-tacrolimus drug-drug interaction in a systemic lupus erythematosus patient with COVID-19
by: Wei Zhang, et al.
Published: (2024-03-01)

Annual editions : drugs, society, and behavior 10/11 /
by: Wilson, Hugh T.
Published: (2010)

Increase of 10% in the Rate of Adverse Drug Reactions for Each Drug Administered in Hospitalized Patients
by: Marisa Rosimeire Ribeiro, et al.
Published: (2018-02-01)

Drug Repurposing of the Antiviral Drug Acyclovir: New Pharmaceutical Salts
by: Paulo Nunes, et al.
Published: (2023-05-01)

Antiretroviral drugs saquinavir and ritonavir reduce inhibitory concentration values of itraconazole against Histoplasma capsulatum strains in vitro
by: Raimunda Sâmia Nogueira Brilhante, et al.
Published: (2016-03-01)